Karen Bush, Ph.D.

Professor of Practice in Biotechnology

Department at Indiana University


Dr. Bush, with a Ph.D. in biochemistry from Indiana University, began her work on β-lactamases and β-lactamase inhibitors at the Squibb Institute for Medical Research in 1977, and continued working in anti-infective research at Bristol-Myers Squibb, Lederle (now part of Pfizer), Astra Zeneca, and Johnson & Johnson until 2009. 


During her pharmaceutical career Dr. Bush worked on the research teams that discovered and developed aztreonam, Zosyn® (piperacillin-tazobactam), levofloxacin, doripenem, ceftobiprole, and the influenza drug peramivir. She also led a microbiology research team that was responsible for the discovery and early development of novel ketolides, oxazolidinones, and fluoroquinolones. Currently she has composed over 210 peer-reviewed publications.

Dr. Bush is currently an Adjunct Professor in the Biology Department and the Biochemistry Department at Indiana University where she teaches in the graduate biotechnology program. She is a Fellow of the American Academy of Microbiology, an Advisor for the Clinical and Laboratory Standards Institute, a past editor of the journal, Antimicrobial Agents & Chemotherapy, and a reviewer for many microbiology journals and NIH study sections.


Leonard E. Post, Director, Ph.D.

Chief Scientific Officer, BioMarin Pharmaceuticals


Dr. Post has over 30 years of experience in all stages of pharmaceutical and biotechnology company R&D from early drug discovery through clinical development and FDA approval. Dr. Post is currently the chief scientific officer of BioMarin Pharmaceuticals, a publicly traded biopharmaceuticals company with four marketed products and five currently in clinical development. In addition, he sits on the Board of Directors of Altiris Therapeutics and Orphagen Pharmaceuticals (two private biotechnology companies) and Viralytics (a public biotechnology company, listed on the Australian Stock Exchange). Prior to joining BioMarin, Dr. Post held various senior research positions at LEAD Therapeutics, Onyx Pharmaceuticals, and Parke-Davis Pharmaceuticals. He received a Bachelor of Science in chemistry from the University of Michigan and a doctorate in biochemistry from the University of Wisconsin, after which he performed a postdoctoral fellowship in virology at the University of Chicago with Dr. Bernard Roizman.

Jehangir Khan, Ph.D.

President, Preclinical Insight Ltd.

Dr. Jehangir K. Khan is the President of Preclinical Insight Ltd, a drug discovery and preclinical development consultancy company. Previously Dr. Khan worked as the Director of Biological Sciences & Pharmaceutical Development at NAEJA Pharmaceutical Inc. In this role, he was actively involved in early discovery Structure Activity Relationship and in different areas of preclinical development such as Drug Metabolism, Pharmacokinetics, Pharmacodynamics, Safety profiling, Preformulation and Bioanalysis. Prior to joining NAEJA, Dr. Khan was the Director of Preclinical Development at Synphar Laboratories Inc.

Over the past two decades Dr. Khan has been part of Research teams in developing  a topical antifungal product currently in the market, several other products in high-risk cardiovascular disease in phase 3, areas of inflammation in phase 2, an anti MRSA topical product in phase 2.

Dr. Khan is a co-inventor of amidine substituted beta-lactam patent with a candidate compound AIC499, a novel resistance breaking antibiotic against a broad range of MDR Gram-Negative Bacteria and diazabicyclooctane beta-lactamase inhibitor patents with a candidate compound Nacubactam (RG-6080, FPI-1459, OP-0595) in clinical development.

Dr. Khan received B.S & M.S degree in Pharmacy from University of Dhaka, Bangladesh and a magna cum laude Doctorate degree from the Faculty of Pharmaceutical Sciences, University of Ghent, Belgium in the field neurotoxin related to neurodegenerative diseases. He has published over 35 articles in professional scientific journals with international circulation and co-inventor in several patents, presented his research findings to at least 20 international meetings, and previously served as a member of International Panel of Experts for evaluation of potential drug candidates for Investigational New Drugs Publications.

In addition to his career in pharmaceutical research Dr. Khan has co-founded Inspire Global Corp Inc, a group of companies involved in e-commerce marketplace business solutions

11629 – 105 Avenue, Edmonton, AB T5H 0L9  |   780-757-5401

© 2017 Fedora Pharmaceuticals Inc. 

  • Facebook - Black Circle
  • LinkedIn - Black Circle